EPS for TTM Technologies, Inc. (TTMI) Expected At $0.40; Last Week Antares Pharma, Inc. (ATRS) Coverage

January 13, 2018 - By Vivian Park

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma had 10 analyst reports since March 9, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Monday, August 7 by Jefferies. H.C. Wainwright initiated the shares of ATRS in report on Friday, September 8 with “Buy” rating. Piper Jaffray maintained the shares of ATRS in report on Monday, October 23 with “Buy” rating. Piper Jaffray maintained it with “Buy” rating and $400 target in Tuesday, July 25 report. The firm has “Buy” rating by H.C. Wainwright given on Monday, October 23. The rating was maintained by Jefferies on Wednesday, March 9 with “Buy”. H.C. Wainwright initiated it with “Buy” rating and $500 target in Friday, June 23 report. The company was maintained on Tuesday, October 10 by Jefferies. As per Wednesday, November 8, the company rating was maintained by H.C. Wainwright. See Antares Pharma, Inc. (NASDAQ:ATRS) latest ratings:

08/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
23/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
23/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $3.0 Maintain
10/10/2017 Broker: Jefferies Rating: Buy New Target: $6.0 Maintain
08/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Initiate
07/08/2017 Broker: Jefferies Rating: Buy New Target: $6.0000 Maintain
25/07/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.0000 Maintain

Analysts expect TTM Technologies, Inc. (NASDAQ:TTMI) to report $0.40 EPS on February, 14.They anticipate $0.16 EPS change or 28.57% from last quarter’s $0.56 EPS. TTMI’s profit would be $40.74M giving it 10.87 P/E if the $0.40 EPS is correct. After having $0.19 EPS previously, TTM Technologies, Inc.’s analysts see 110.53% EPS growth. The stock increased 3.51% or $0.59 during the last trading session, reaching $17.39. About 1.16 million shares traded or 17.97% up from the average. TTM Technologies, Inc. (NASDAQ:TTMI) has risen 142.01% since January 13, 2017 and is uptrending. It has outperformed by 125.31% the S&P500.

The stock decreased 0.44% or $0.01 during the last trading session, reaching $2.28. About 859,065 shares traded. Antares Pharma, Inc. (NASDAQ:ATRS) has risen 207.14% since January 13, 2017 and is uptrending. It has outperformed by 190.44% the S&P500.

Investors sentiment decreased to 1.29 in 2017 Q3. Its down 0.78, from 2.07 in 2017Q2. It fall, as 11 investors sold Antares Pharma, Inc. shares while 23 reduced holdings. 18 funds opened positions while 26 raised stakes. 53.56 million shares or 0.15% less from 53.64 million shares in 2017Q2 were reported. Blackrock holds 0% or 9.26 million shares in its portfolio. Deutsche Bancorporation Ag has 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS) for 739,608 shares. Gsa Capital Partners Ltd Liability Partnership invested in 182,075 shares or 0.04% of the stock. Wells Fargo And Mn accumulated 1.34 million shares. 366,000 were reported by Perkins Management. Armistice Capital Limited Liability accumulated 4.20M shares or 1.6% of the stock. Pnc Svcs Gp Incorporated holds 0% or 100,000 shares. Amer Group Inc stated it has 96,335 shares or 0% of all its holdings. M&T Fincl Bank Corp stated it has 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Principal Grp holds 24,784 shares. Panagora Asset Management holds 0.01% or 403,465 shares in its portfolio. Manufacturers Life Insurance The has 119,903 shares for 0% of their portfolio. Voya Mgmt Limited holds 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 65,073 shares. Aqr Management Llc stated it has 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). New York State Common Retirement Fund stated it has 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS).

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $357.22 million. The companyÂ’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

Since October 3, 2017, it had 0 insider purchases, and 2 insider sales for $1.04 million activity. GARRITY THOMAS J had sold 30,000 shares worth $105,000. JACOB LEONARD S had sold 230,000 shares worth $931,920 on Monday, October 9.

TTM Technologies, Inc., together with its subsidiaries, makes printed circuit boards worldwide. The company has market cap of $1.77 billion. It provides a range of PCBs and electro-mechanical solutions, including conventional PCBs, high density interconnect PCBs, flexible PCBs, rigid-flex PCBs, custom assemblies and system integration products, and IC substrates. It has a 25.99 P/E ratio. It also produces test specialized circuits that are used in radio-frequency or microwave emission and collection applications; printed circuits with heavy copper cores, and embedded and press-fit coins; PCBs with electrically passive heat sinks; and PCBs with electrically active thermal cores.

Among 6 analysts covering TTM Tech (NASDAQ:TTMI), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. TTM Tech had 19 analyst reports since August 6, 2015 according to SRatingsIntel. TheStreet downgraded TTM Technologies, Inc. (NASDAQ:TTMI) on Friday, September 4 to “Sell” rating. The firm has “Buy” rating given on Thursday, August 6 by Needham. The rating was downgraded by JP Morgan to “Neutral” on Friday, February 17. JP Morgan upgraded it to “Overweight” rating and $21 target in Tuesday, April 4 report. Stifel Nicolaus downgraded TTM Technologies, Inc. (NASDAQ:TTMI) rating on Friday, July 28. Stifel Nicolaus has “Hold” rating and $1900 target. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, September 27 report. The company was maintained on Thursday, October 27 by Needham. The stock of TTM Technologies, Inc. (NASDAQ:TTMI) earned “Buy” rating by Needham on Tuesday, October 3. Needham upgraded it to “Strong Buy” rating and $22 target in Monday, August 7 report. Stifel Nicolaus upgraded the stock to “Hold” rating in Monday, August 10 report.

Investors sentiment decreased to 1.01 in 2017 Q3. Its down 0.20, from 1.21 in 2017Q2. It is negative, as 41 investors sold TTM Technologies, Inc. shares while 63 reduced holdings. 28 funds opened positions while 77 raised stakes. 104.71 million shares or 4.13% more from 100.55 million shares in 2017Q2 were reported. Sterling Ltd Liability Corporation accumulated 170,992 shares or 0.02% of the stock. Moreover, Arizona State Retirement Systems has 0.01% invested in TTM Technologies, Inc. (NASDAQ:TTMI) for 47,525 shares. Credit Suisse Ag holds 107,008 shares. Alpha Windward Limited Liability Company accumulated 0.34% or 35,580 shares. Kennedy Cap Mgmt Incorporated has 2.21M shares. Macquarie Grp Incorporated Limited holds 0.06% or 2.22M shares in its portfolio. 186,710 were accumulated by Wells Fargo And Company Mn. Tower Rech Cap Lc (Trc) holds 0.01% or 10,298 shares in its portfolio. Pacad invested in 500 shares. Citigroup reported 116,712 shares. First Manhattan stated it has 0% of its portfolio in TTM Technologies, Inc. (NASDAQ:TTMI). Bancshares Of America Corporation De reported 222,476 shares. Nationwide Fund Advisors owns 89,042 shares. Jane Street Group Inc Ltd Liability Corporation invested in 31,453 shares. Timpani Mngmt Limited Liability Corporation holds 72,198 shares.